News ResMed, Inc.

Equities

RMD

US7611521078

Real-time Estimate Cboe BZX Other stock markets 10:34:57 2024-04-24 am EDT			5-day change	1st Jan Change
183.8 ^USD	-0.26%		+6.05%	+7.17%

Apr. 17	Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	RE
Apr. 01	Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	Apr. 17	RE
ResMed AirSense 10 AutoSet: Empowering Sleep Health with Positive Airway Pressure Therapy	Apr. 16	AQ
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024	Apr. 04	GL
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024	Apr. 04	AQ
Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	Apr. 01	MT
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis	Mar. 15	GL
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis	Mar. 15	AQ
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask	Mar. 06	GL
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask	Mar. 06	AQ
ResMed Inc. Announces the U.S. Launch of the AirFit F40	Mar. 06	CI
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight	Mar. 05	MT
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target is AU$31	Mar. 04	MT
FTSE 100 Edges Higher on Leap Day, Boosted by Howden Joinery, Haleon Gains	Feb. 29	DJ
ResMed Unveils AirSense 11 AutoSet: Revolutionizing Sleep Apnea Treatment	Feb. 20	AQ
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea	Feb. 12	GL
Australia shares slip as biotech firm CSL slumps on failed drug trial (Feb 12)	Feb. 11	RE
Ex-dividend day	Feb. 06	FA
Powell, the paper tiger	Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
Weekly Top Ten News Stories - 2 February 2024	Feb. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ResMed, Inc. continues to make headway in the sleep market

December 11, 2023 at 05:55 am EST